September 4, 2012Infectious Diseaseadmin Alnylam Pharmaceuticals, Inc. , a leading RNAi therapeutics company, announced today complete results from its Phase IIb trial with ALN-RSV01 for the treatment of respiratory syncytial virus infection in lung transplant patients.
